NCT07303855 Effectiveness of Goal-Directed Fluid Therapy Guided by Cardiac Index Versus Central Venous Pressure in Major Abdominal Surgery Patients in the ICU.
| NCT ID | NCT07303855 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitas Indonesia |
| Condition | Elective Major Abdominal Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-12-01 with a primary completion date of 2026-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare two different methods for guiding intravenous (IV) fluid therapy in patients during their first 6 hours in the ICU after major abdominal surgery. The goal is to determine which method leads to a more optimal and precise amount of fluid administration. The objective is to compare the total fluid volumes administered when guided by Cardiac Index versus Central Venous Pressure, as well as mortality, length of stay, relaparotomy and reintubation in order to identify the more precise fluid management strategy for postoperative ICU patients.
Eligibility Criteria
Inclusion Criteria: * Adult patients aged 18 to 65 years. * Patients with a Body Mass Index (BMI) between 18 and 30 kg/m². * Patients undergoing elective major abdominal surgery with a planned postoperative admission to the ICU. * Patients with an American Society of Anesthesiologists (ASA) physical status classification of I to III. Exclusion Criteria: * Patients with pre-operative cardiovascular disorders (Coronary Artery Disease, or heart failure NYHA Class III and IV). * Patients with severe renal impairment (Chronic Kidney Disease Stage V) with or without hemodialysis and fluid restrictions. * Non-sinus cardiac rhythm. * Pregnancy. * Patients with right heart failure (patients with signs of congestion and symptoms of right heart failure accompanied by evidence of reduced right ventricular function, indicated by TAPSE \< 17 mm). * Patients with pulmonary hypertension (patients with echocardiographic suspicion of tricuspid regurgitation, tricuspid regurgitation velocity \> 3.4 m/s, or mean pulmonary artery pressure \> 20 mmHg from right heart catheterization). * Patients with Acute Respiratory Distress Syndrome (ARDS) or patients requiring specialized ventilation modes. * Patients who refuse to participate in the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07303855 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Elective Major Abdominal Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07303855 currently recruiting?
Yes, NCT07303855 is actively recruiting participants. Contact the research team at maninjau3@gmail.com for enrollment information.
Where is the NCT07303855 trial being conducted?
This trial is being conducted at Jakarta Pusat, Indonesia.
Who is sponsoring the NCT07303855 clinical trial?
NCT07303855 is sponsored by Universitas Indonesia. The trial plans to enroll 60 participants.